Rapid Urine Test Evaluated for Helicobacter Pylori Infection
|
By LabMedica International staff writers Posted on 26 Jun 2014 |
|
Image: Rapirun Helicobacter pylori Antibody Stick. The urine sample is considered positive when two red bands at the test line and control line (arrows) are observed after 15 minutes and is considered negative when only the control line is observed. The absence of a control line indicates an invalid result (Photo courtesy of Duc T Quach).
Image: The PyloriTek rapid urease test to detect Helicobacter pylori (Photo courtesy of Serim Research Co.).
A rapid urine test based on enzyme-linked immunosorbent assay (ELISA) has been developed for the detection of anti-Helicobacter Pylori antibodies in urine.
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
 Assay.jpg)
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Electrolyte Analyzer
CBS-4000 (CBS-400)
HPV Molecular Test
BD Onclarity HPV Assay
Latest Immunology News
- New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
- Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
- Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
- Airway Immune Signature May Predict Tuberculosis Progression Risk
- New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
- Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
- Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Molecular Diagnostics
view channel
New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
Chemotherapy resistance hampers treatment of triple-negative breast cancer (TNBC), particularly in tumors with TP53 mutations. Identifying biomarkers that signal resistance while pointing to actionable... Read more
Blood-Based Gene Expression Test Detects Early Pancreatic Cancer
Pancreatic cancer remains difficult to detect at a curable stage and is associated with poor survival outcomes. In Japan, the five-year relative survival rate is 8.5%, while early-stage disease accounts... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read morePathology
view channel
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more
